Institutional marketing in the pharmaceutical industry represents a specialized and strategically significant segment of healthcare product distribution that focuses on supplying medicines and healthcare products directly to institutions such as government hospitals, private hospital chains, defense establishments, railways, public health programs, and non-governmental organizations. Unlike retail pharmaceutical marketing, which primarily targets individual physicians and pharmacies, institutional marketing operates through structured procurement systems, tender-based purchasing, rate contracts, and centralized supply mechanisms. This system plays a critical role in ensuring large-scale drug availability, affordability, and accessibility across public and private healthcare infrastructures. In India, institutional marketing has gained increasing importance due to the expansion of government-sponsored health schemes, rising hospital infrastructure, and large-scale public procurement programs. Regulatory authorities such as the Central Drugs Standard Control Organization and pricing regulators like the National Pharmaceutical Pricing Authority influence pricing policies, compliance requirements, and quality standards that directly impact institutional sales strategies. Additionally, procurement platforms such as the Government e Marketplace have introduced transparency, digitalization, and competitive bidding mechanisms into the pharmaceutical supply chain. This case study explores the structural framework, operational mechanisms, marketing strategies, ethical considerations, regulatory environment, and economic implications of institutional marketing practices in the pharmaceutical industry. It examines how pharmaceutical companies participate in open and limited tenders, technical and financial bid submissions, and L1 (lowest bidder) selection systems while maintaining compliance with national drug regulations and ethical marketing guidelines issued by organizations such as the World Health Organization. The study also highlights the differences between retail and institutional marketing in terms of pricing strategy, relationship management, bulk purchasing agreements, distribution logistics, and payment cycles. Furthermore, the study evaluates key marketing approaches such as key account management, strategic pricing models, portfolio positioning, supply reliability assurance, and post-procurement service support. Ethical challenges including transparency issues, delayed payments, price control regulations, and intense market competition are critically analyzed. The role of policy frameworks such as Drug Price Control Order (DPCO) and Uniform Code for Pharmaceutical Marketing Practices (UCPMP) is also discussed to understand their influence on fair competition and responsible marketing behavior. The pharmacoeconomic perspective of institutional marketing is assessed by examining cost-effectiveness, generic substitution, bulk procurement advantages, and the impact of competitive bidding on healthcare affordability. Through a systematic analysis of procurement processes and real-world institutional participation models, this case study demonstrates how institutional marketing serves as a backbone of large-scale medicine distribution while balancing profitability, regulatory compliance, and public health objectives. In conclusion, institutional marketing in the pharmaceutical industry is not merely a sales function but a complex, policy-driven, compliance-oriented, and strategically managed domain that significantly contributes to healthcare delivery systems. The evolving digital procurement ecosystem, increasing regulatory scrutiny, and emphasis on ethical standards are shaping the future of institutional pharmaceutical marketing in India and globally.